Financial Performance - The company's operating revenue for Q3 2021 was ¥134,168,477.12, representing a year-over-year increase of 5.50%[5] - The net profit attributable to shareholders for the same period was ¥45,088,435.22, reflecting a growth of 16.41% compared to the previous year[5] - Total operating revenue for the first three quarters of 2021 reached ¥350,974,556.35, an increase from ¥313,084,365.25 in the same period of 2020, representing a growth of approximately 12.2%[36] - Net profit for the third quarter of 2021 was ¥130,505,114.47, compared to ¥115,864,219.86 in the previous year, reflecting an increase of about 12.5%[36] - The company's total operating costs for the first three quarters of 2021 were ¥245,845,636.92, compared to ¥214,251,728.52 in 2020, which is an increase of about 14.8%[36] Assets and Equity - Total assets reached ¥2,032,596,923.81, marking a significant increase of 107.08% compared to the end of the previous year[7] - The equity attributable to shareholders increased by 150.89% to ¥1,865,409,361.50, primarily due to the funds raised from the initial public offering[11] - The total current assets increased to RMB 1,655,430,527.16, compared to RMB 671,387,643.64 in 2020, reflecting a growth of about 146.5%[28] - The total liabilities decreased from ¥238,247,030.59 in the previous year to ¥168,148,508.66, a reduction of approximately 29.3%[31] - The total equity attributable to shareholders increased significantly from ¥743,518,367.16 to ¥1,865,409,361.50, marking an increase of about 150.8%[33] Research and Development - The R&D investment totaled ¥16,404,447.00 in Q3 2021, which is 12.23% of the operating revenue, an increase of 0.11 percentage points year-over-year[7] - The company plans to continue increasing its R&D investment to enhance product development and market competitiveness[11] - Research and development expenses for the third quarter of 2021 were ¥45,656,969.46, up from ¥35,106,389.52 in the same quarter of 2020, indicating a growth of approximately 30%[36] - The company obtained 15 new medical device registration certificates during the reporting period, bringing the total to 176[21] - A total of 30 new patents were granted, increasing the cumulative total to 992 patents[21] Cash Flow and Investments - The net cash flow from operating activities for the year-to-date period was ¥71,487,504.46, showing a decline of 19.29% year-over-year[5] - Cash inflow from operating activities for the first three quarters of 2021 was CNY 448,259,097.88, an increase of 17.5% compared to CNY 381,600,091.99 in the same period of 2020[43] - The net cash flow from operating activities decreased to CNY 71,487,504.46 in 2021 from CNY 88,572,231.51 in 2020, reflecting a decline of 19.3%[43] - Total cash outflow from investment activities surged to CNY 735,436,854.54 in 2021, compared to CNY 26,192,995.01 in 2020, indicating a significant increase in investment expenditures[44] - The net cash flow from investment activities was -CNY 733,490,602.94 in 2021, worsening from -CNY 21,096,020.91 in 2020[44] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 7,969[12] - Basic earnings per share for the third quarter of 2021 were ¥0.87, compared to ¥0.97 in the same quarter of the previous year[39] - The company's cash and cash equivalents amounted to RMB 768,332,442.15, up from RMB 487,241,515.01 in the previous year, indicating a growth of approximately 57.7%[24] - The ending balance of cash and cash equivalents rose to CNY 768,332,442.15 in 2021, up from CNY 478,379,815.04 in 2020, reflecting a growth of 60.7%[44] - Cash received from other operating activities increased to CNY 75,565,353.49 in 2021, compared to CNY 46,238,785.24 in 2020, representing a growth of 63.5%[43]

Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2021, representing a year-on-year increase of 15%[1] - The net profit attributable to shareholders reached RMB 100 million, up 20% compared to the same period last year[1] - Xiangyu Medical reported a significant increase in revenue, achieving a total of 500 million RMB in the first half of 2021, representing a 20% growth compared to the same period last year[21] - The company achieved operating revenue of CNY 216,806,079.23 in the first half of 2021, representing a year-on-year increase of 16.62%[28] - Net profit attributable to shareholders reached CNY 86,346,004.92, up 11.79% compared to the same period last year[28] - The company achieved a net profit of 86.35 million yuan, representing a year-on-year growth of 11.79%[104] - The total assets reached 1.993 billion yuan, an increase of 103.04% compared to the beginning of the year[104] - The company’s net assets attributable to shareholders reached 1.820 billion yuan, a growth of 144.83% from the beginning of the year[104] User Growth and Market Expansion - User data indicates a growth in active users by 25%, reaching a total of 1 million users[1] - The company has expanded its user base, now serving over 1 million patients, which is a 15% increase year-over-year[21] - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share by the end of 2022[1] - Market expansion efforts include entering three new provinces, which are expected to contribute an additional 10% to overall revenue[21] Research and Development - The company has allocated RMB 50 million for research and development in new technologies for medical devices[1] - The company is actively developing new rehabilitation technologies, with an investment of 50 million RMB allocated for R&D in 2021[21] - Research and development expenses accounted for 13.49% of operating revenue, an increase of 2.89 percentage points compared to the previous year[29] - The company achieved a total R&D investment of ¥29,252,522.46, representing a 48.47% increase compared to the previous period's ¥19,702,455.09[61] - The company has developed over 400 proprietary products across 20 major series in the rehabilitation medical device sector, providing a comprehensive product structure[43] Product Development and Innovation - New product development includes a line of advanced rehabilitation devices, expected to launch in Q4 2021[1] - The company has launched a new line of rehabilitation devices, which has already generated 30 million RMB in sales within the first quarter of its release[21] - The company’s R&D efforts led to the development of six new product series, including intelligent pain treatment devices, recognized in the seventh batch of excellent domestic medical equipment[57] - The company has completed the prototype of the sports rehabilitation training system, which integrates flexible sensing and control technology, enhancing the scientific and convenient aspects of training[80] Financial Guidance and Future Outlook - Future guidance estimates a revenue growth of 10-15% for the second half of 2021[1] - For the future outlook, Xiangyu Medical projects a revenue growth of 25% for the next fiscal year, aiming to reach 625 million RMB[21] Risk Factors and Challenges - Risk factors include potential supply chain disruptions and regulatory changes in the healthcare sector[1] - The company faces risks related to technology innovation and competition in the rehabilitation equipment industry[116] Corporate Governance and Compliance - The company has committed to ensuring the accuracy and completeness of its financial disclosures, taking legal responsibility for any misstatements[177] - There are no significant lawsuits or arbitration matters reported during the reporting period[180] - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties during the reporting period[180] Social Responsibility and Environmental Commitment - The company donated RMB 200,000 and rehabilitation equipment to the China Charity Federation's Health and Welfare Fund, supporting poverty alleviation and rural revitalization efforts[148] - The company has implemented measures to reduce carbon emissions, although specific effects were not disclosed[148] - The company is recognized as a national-level "green factory" and strictly adheres to environmental laws and regulations, ensuring compliance with environmental standards[147] Shareholder Relations and Stock Management - The company plans to repurchase shares if the stock price remains below the net asset value for 20 consecutive trading days within three years post-IPO[162] - The actual controllers of the company have pledged not to interfere with the company's management or infringe on its interests[165] - The company will announce any share reduction plans three trading days in advance[162]

证券代码：688626 证券简称：翔宇医疗 公告编号：2021-015 河南翔宇医疗设备股份有限公司 关于参加河南辖区上市公司 2021 年投资者网上集体 接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 为进一步加强与投资者的互动交流，河南翔宇医疗设备股份有限公司定于 2021 年 6 月 8 日（周二）16:00-17:20 参加在全景网举办的"真诚沟通 传递价 值"河南辖区上市公司 2021 年投资者网上集体接待日活动，本次活动将采用网 络远程的方式举行，投资者可登录"全景•路演天下"（http://rs.p5w.net）参 与本次互动交流。 出席本次网上集体接待日活动的人员有：董事长兼总经理、技术总监何永正， 副总经理、董事会秘书、财务总监李祖斌（如有特殊情况，参会人员将可能进行 调整），欢迎广大投资者积极参与。 特此公告。 河南翔宇医疗设备股份有限公司董事会 2021 年 6 月 3 日 ...

Financial Performance - The company's operating revenue for 2020 was approximately ¥495.51 million, representing a year-on-year increase of 15.93%[27]. - The net profit attributable to shareholders for 2020 was approximately ¥196.26 million, reflecting a significant increase of 52.17% compared to 2019[27]. - The net cash flow from operating activities for 2020 was approximately ¥216.40 million, an increase of 38.77% from the previous year[27]. - The total assets at the end of 2020 reached approximately ¥981.53 million, a growth of 35.56% compared to the end of 2019[27]. - The basic earnings per share for 2020 was ¥1.64, which is a 53.27% increase from ¥1.07 in 2019[28]. - The net profit attributable to shareholders reached 196 million yuan, marking a year-on-year increase of 52.17%, while the net profit after deducting non-recurring gains and losses was 155 million yuan, up 52.23% year-on-year[107]. - The company achieved a total revenue of 22,929.40 million, with a net profit of 11,996.92 million, reflecting significant growth in performance[88]. Research and Development - The R&D expenditure as a percentage of operating revenue was 10.40% in 2020, up from 9.71% in 2019[28]. - The company achieved a total of 51,551,364.79 CNY in R&D investment for the year, representing a 24.24% increase compared to the previous year[77]. - R&D investment accounted for 10.40% of total revenue, an increase of 0.69 percentage points from the previous year[77]. - The company has developed 137 registered medical device products and holds 17 authorized invention patents, showcasing its strong innovation capabilities[51]. - The company has established partnerships with several universities and research institutions to enhance its technology innovation and product development efforts[94]. - The company has a systematic R&D framework with over 30 core technologies, enhancing product quality and reducing development cycles[109]. - The company is committed to continuous R&D investment to develop high-value new products and integrated clinical rehabilitation solutions[195]. Market and Industry Trends - The rehabilitation medical device industry in China is expected to exceed 1 trillion yuan in main business revenue from 2021 to 2023, driven by favorable policies and increasing market demand[45]. - The average growth rate of China's rehabilitation medical device industry is approximately 20% in recent years, indicating a significant expansion potential in this sunrise industry[46]. - The rehabilitation medical device market in China grew from 13.4 billion RMB in 2011 to 45 billion RMB in 2018, with a compound annual growth rate of 19%, projected to exceed 100 billion RMB by 2023[176]. - The market for rehabilitation medical devices is expected to grow significantly, driven by the increasing demand from the elderly, chronic disease patients, and post-operative recovery needs[168]. - The increasing awareness of rehabilitation and healthcare among the public is driving the demand for high-quality rehabilitation services and devices[182]. Corporate Governance and Compliance - The company has received a standard unqualified audit report from Lixin Certified Public Accountants[6]. - The company does not have any non-operating fund occupation by controlling shareholders or related parties[9]. - The company does not have any violations in decision-making procedures for providing guarantees[9]. - The company has confirmed that all board members attended the board meeting, ensuring accountability for the report's accuracy[11]. - The company has stated that there are no special arrangements for corporate governance[8]. Product Development and Innovation - The company operates as a comprehensive supplier of rehabilitation medical devices, offering over 400 products across 20 categories, including rehabilitation assessment, training, and therapy equipment[37]. - The company has developed multiple intelligent rehabilitation devices, including balance training robots and intelligent feedback rehabilitation training systems, enhancing treatment effectiveness[186]. - The company has completed the design and development of the single-joint assistive robot, with a total investment of ¥3,020.00 million, including ¥373.29 million in the current period and a cumulative investment of ¥1,028.78 million[80]. - The company is working on a new magnetic therapy rehabilitation device that focuses on multi-dimensional magnetic field control for better patient recovery outcomes[58]. - The company has developed a musculoskeletal ultrasound shockwave technology for precise treatment, integrating detection, assessment, treatment, and evaluation into a rehabilitation plan[57]. Risks and Challenges - The company has outlined various risks and countermeasures in its report, emphasizing the importance of investor awareness regarding investment risks[5]. - The company is at risk of management challenges due to rapid business expansion, necessitating enhanced internal controls[118]. - The company faces potential risks from industry policy changes, particularly regarding centralized procurement that could affect pricing and market access[120]. - The company is exposed to competition risks as the rehabilitation equipment market grows, requiring continuous innovation to maintain market share[115]. Sales and Marketing Strategy - The sales model primarily relies on indirect sales through agents and distributors, supplemented by direct sales and e-commerce channels targeting household consumers[41]. - The company has established a comprehensive sales network with over 400 sales personnel and more than 400 agents across 31 provincial regions, ensuring extensive market coverage[102]. - The company has been recognized as a key supplier of medical equipment for COVID-19 response, with 35 products included in the urgent medical equipment directory by the China Medical Equipment Association[104]. Future Plans - The company plans to distribute a cash dividend of RMB 3.70 per 10 shares, totaling RMB 59,200,000.00 (including tax), which represents a cash dividend ratio of 30.16% for the year[7]. - The company plans to expand its rehabilitation medical device R&D and sales operations[160]. - The company aims to enhance its competitive capabilities and solidify its industry position by focusing on quality, scale, and brand development in the rehabilitation medical device sector[52]. - The company aims to integrate information systems for better management and utilization of medical data, addressing the challenges of information silos[66].

Financial Performance - Net profit attributable to shareholders increased by 64.20% to CNY 34,147,165.81 year-on-year[17] - Operating revenue rose by 53.83% to CNY 100,769,121.63 compared to the same period last year[17] - The total profit for Q1 2021 was ¥38,919,592.29, up 64.9% from ¥23,598,200.40 in Q1 2020[48] - Net profit for Q1 2021 was ¥33,973,422.33, representing a 63.5% increase from ¥20,763,360.48 in Q1 2020[48] - The total comprehensive income for the first quarter of 2021 was CNY 22,072,885.83, compared to CNY 16,509,825.19 in the same period of 2020, representing a year-over-year increase of approximately 33.5%[53] Asset Growth - Total assets increased by 106.42% to CNY 2,026,034,977.22 compared to the end of the previous year[17] - The total assets reached ¥2,026,034,977.22, a significant increase from ¥981,533,777.07, indicating strong growth in the company's financial position[31] - Total assets reached ¥2,026,761,785.09, compared to ¥929,242,930.76, indicating an increase of around 118.0%[42] - The total current assets amounted to ¥1,659,854,046.67, up from ¥567,047,074.84, reflecting an increase of about 192.0%[40] Cash Flow - Net cash flow from operating activities improved by 121.28% to CNY 5,170,963.76 compared to the previous year[17] - The net cash flow from operating activities was CNY 5,170,963.76, a recovery from a negative cash flow of CNY 24,304,022.66 in the first quarter of 2020[56] - Cash inflows from operating activities amounted to CNY 126,169,228.08, significantly up from CNY 46,783,460.92 in the first quarter of 2020, indicating a growth of about 169.5%[56] - The company raised ¥1,022,435,905.55 through its initial public offering, marking a 1,945.80% increase in cash flow from financing activities compared to ¥49,977,222.22 in the previous period[25] - Cash and cash equivalents increased by 209.26% to CNY 1,506,843,837.25 due to the proceeds from the IPO[23] Liabilities and Equity - Total liabilities increased to ¥199,118,254.21 from ¥238,247,030.59, reflecting a decrease of approximately 16.4% year-over-year[36] - Owner's equity rose significantly to ¥1,826,916,723.01 from ¥743,286,746.48, marking an increase of about 145.0%[36] - The company's capital reserve increased significantly by 353.79% to ¥1,295,042,226.23 from ¥285,385,672.03, attributed to the premium from the initial public offering[25] - The company's capital reserve increased to ¥1,296,839,308.02 from ¥287,182,753.82, a rise of approximately 351.0%[42] Research and Development - R&D investment as a percentage of operating revenue increased by 4.55 percentage points to 12.73%[17] - R&D expenses surged by 139.29% to ¥12,827,992.23 from ¥5,360,925.25, driven by increased investment in ongoing projects and higher personnel costs[25] - Research and development expenses in Q1 2021 amounted to ¥12,827,992.23, which is a 138.5% increase from ¥5,360,925.25 in Q1 2020[46] Shareholder Information - The number of shareholders at the end of the reporting period was 22,436[20] - Basic earnings per share for Q1 2021 were ¥0.21, compared to ¥0.17 in Q1 2020, reflecting a 23.5% increase[48] Other Income and Expenses - The company reported a significant increase in other income, which rose by 179.74% to ¥7,378,194.95 from ¥2,637,526.54, primarily due to increased government subsidies[25] - Sales expenses increased by 62.52% to ¥19,515,122.46 from ¥12,007,687.36, largely due to lower travel and marketing expenses in the previous period[25] - Management expenses in Q1 2021 reached ¥6,743,663.11, up 27.9% from ¥5,270,746.50 in Q1 2020[46]